PT3320912T - Imunoterapia à base de indoleamina 2,3-dioxigenase - Google Patents
Imunoterapia à base de indoleamina 2,3-dioxigenaseInfo
- Publication number
- PT3320912T PT3320912T PT171946197T PT17194619T PT3320912T PT 3320912 T PT3320912 T PT 3320912T PT 171946197 T PT171946197 T PT 171946197T PT 17194619 T PT17194619 T PT 17194619T PT 3320912 T PT3320912 T PT 3320912T
- Authority
- PT
- Portugal
- Prior art keywords
- indoleamine
- based immunotherapy
- dioxygenase
- dioxygenase based
- immunotherapy
- Prior art date
Links
- 238000009169 immunotherapy Methods 0.000 title 1
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 title 1
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
- C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
- C12Y113/11052—Indoleamine 2,3-dioxygenase (1.13.11.52), i.e. indoleamine 2,3-dioxygenase 1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200800565 | 2008-04-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3320912T true PT3320912T (pt) | 2021-05-24 |
Family
ID=40873320
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT97535561T PT2280721T (pt) | 2008-04-17 | 2009-04-17 | Imunoterapia à base de indoleamina 2,3-dioxigenase |
| PT171946197T PT3320912T (pt) | 2008-04-17 | 2009-04-17 | Imunoterapia à base de indoleamina 2,3-dioxigenase |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT97535561T PT2280721T (pt) | 2008-04-17 | 2009-04-17 | Imunoterapia à base de indoleamina 2,3-dioxigenase |
Country Status (20)
| Country | Link |
|---|---|
| US (6) | US9433666B2 (pt) |
| EP (3) | EP3915570A1 (pt) |
| JP (2) | JP2011520783A (pt) |
| CN (2) | CN102088994B (pt) |
| AU (1) | AU2009253539B2 (pt) |
| CA (1) | CA2721150C (pt) |
| CY (2) | CY1120352T1 (pt) |
| DK (2) | DK3320912T3 (pt) |
| ES (2) | ES2870596T3 (pt) |
| HR (2) | HRP20180282T1 (pt) |
| HU (2) | HUE055338T2 (pt) |
| IL (1) | IL208781A (pt) |
| LT (2) | LT3320912T (pt) |
| NO (1) | NO2280721T3 (pt) |
| NZ (1) | NZ588757A (pt) |
| PL (2) | PL2280721T3 (pt) |
| PT (2) | PT2280721T (pt) |
| SI (2) | SI3320912T1 (pt) |
| WO (1) | WO2009143843A1 (pt) |
| ZA (1) | ZA201008056B (pt) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011520783A (ja) | 2008-04-17 | 2011-07-21 | エルレフ ホスピタル | インドールアミン２，３−ジオキシゲナーゼに基づく免疫療法 |
| EP2425830A1 (en) * | 2010-09-03 | 2012-03-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Synergistic drug combination for the treatment of cancer |
| GB201315946D0 (en) * | 2013-09-06 | 2013-10-23 | Immune Targeting Systems Its Ltd | Oncology vaccine |
| EP3149047A1 (en) * | 2014-05-29 | 2017-04-05 | Spring Bioscience Corporation | Anti- indoleamine 2,3-dioxygenase 1 antibodies and diagnostic uses thereof |
| CA2959197C (en) * | 2014-09-17 | 2023-03-14 | Herlev Hospital | Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof |
| CN106148276A (zh) * | 2015-04-16 | 2016-11-23 | 中国科学院上海生命科学研究院 | 间充质干细胞在制备治疗神经退行性疾病的药物中的应用 |
| BR112017027653A2 (pt) | 2015-06-29 | 2018-08-28 | Ose Immunotherapeutics | método para induzir a resposta de memória t precoce com vacina anti-tumoral de peptídeos curtos |
| US11298413B2 (en) | 2015-09-16 | 2022-04-12 | Io Biotech Aps | Vaccine compositions comprising C—C motif chemokine 22 (CCL22) or fragments thereof |
| PL3423087T3 (pl) * | 2016-03-04 | 2024-05-20 | Io Biotech Aps | Skojarzona terapia przeciwnowotworowa |
| CN109803674A (zh) | 2016-06-10 | 2019-05-24 | Io生物技术公司 | Calr和jak2疫苗组合物 |
| JP2019537432A (ja) * | 2016-10-04 | 2019-12-26 | ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド | 標的化エフェクタータンパク質およびその使用 |
| DK3526347T3 (da) * | 2016-10-14 | 2021-02-15 | Univ Zuerich | Indolamin-2,3-dioxygenase-analyse til diagnose og prognose af prostatacancer |
| EA201991444A1 (ru) | 2017-01-27 | 2019-12-30 | Имматикс Байотекнолоджиз Гмбх | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака |
| HRP20230512T8 (hr) | 2017-01-27 | 2023-09-15 | Immatics Biotechnologies Gmbh | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma jajnika i drugih karcinoma |
| MA47367B1 (fr) * | 2017-01-27 | 2023-06-28 | Immatics Biotechnologies Gmbh | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers |
| WO2019075062A1 (en) | 2017-10-11 | 2019-04-18 | University Of Florida Research Foundation | MODIFIED GAL-1 PROTEINS AND USES THEREOF |
| KR102624844B1 (ko) | 2017-11-27 | 2024-01-12 | 오제 이뮈노테라프틱스 | 암의 향상된 치료 |
| CN109758467B (zh) * | 2019-03-08 | 2020-12-25 | 中国农业科学院兰州兽医研究所 | 一种吉西他滨在制备预防口蹄疫病毒感染的药物中的应用 |
| KR20220092905A (ko) * | 2019-10-23 | 2022-07-04 | 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 | 입양 면역요법 |
| CN112881269A (zh) * | 2021-02-23 | 2021-06-01 | 浙江正熙生物技术股份有限公司 | 一种流式荧光检测试剂的质量检测方法 |
| GB202103673D0 (en) | 2021-03-17 | 2021-04-28 | Io Biotech Aps | Combination therapy for cancer |
| WO2023161350A1 (en) | 2022-02-24 | 2023-08-31 | Io Biotech Aps | Nucleotide delivery of cancer therapy |
| CN114657158B (zh) * | 2022-05-25 | 2022-10-21 | 深圳吉诺因生物科技有限公司 | Ido1相关疫苗及其应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US58767A (en) | 1866-10-16 | John brougjbton | ||
| US5554372A (en) | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
| BR9608804A (pt) * | 1995-06-20 | 1999-02-17 | Merck & Co Inc | Processos para sintetizar (1s,2r) indandiol para sintetizar (1s) amino (2r) indanol substancialmente isento de qualquer estereoisômero de bio-resolução para remover cis (1s,2r) indandiol de uma mistura de cis (1s,2r) indandiol e cis (1r,2s) indandiol e cultura pura |
| US6096313A (en) | 1996-02-09 | 2000-08-01 | Ludwig Institute For Cancer Research | Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant |
| EP0956046A4 (en) | 1996-06-12 | 2004-10-20 | Yajun Guo | CELLULAR VACCINALS AND IMMUNOTHERAPEUTICS AND METHOD FOR THE PRODUCTION THEREOF |
| CN1223688A (zh) * | 1996-06-27 | 1999-07-21 | 纳幕尔杜邦公司 | 对羟基苯丙酮酸双加氧酶的植物基因 |
| DE19730066A1 (de) * | 1997-07-14 | 1999-01-21 | Basf Ag | DNA-Sequenz codierend für eine Hydroxyphenylpyruvatdioxygenase und deren Überproduktion in Pflanzen |
| US6451840B1 (en) | 1997-12-05 | 2002-09-17 | Medical College Of Georgia Research Institute, Inc. | Regulation of T cell-mediated immunity by tryptophan |
| WO2000066764A1 (en) | 1999-05-03 | 2000-11-09 | Ludwig Institute For Cancer Research | Methods for increasing t cell proliferation |
| MXPA03006617A (es) | 2001-01-24 | 2004-12-02 | Protein Design Labs Inc | Metodos de diagnostico de cancer de pecho, composiciones y metodos de rastreo de moduladores de cancer de pecho. |
| AU2002258518A1 (en) | 2001-03-14 | 2002-09-24 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer |
| AU2002318944A1 (en) | 2001-08-01 | 2003-02-17 | Coley Pharmaceutical Gmbh | Methods and compositions relating to plasmacytoid dendritic cells |
| WO2003020884A2 (en) | 2001-08-14 | 2003-03-13 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services | Method for rapid generation of mature dendritic cells |
| EP2177601A1 (en) | 2002-04-12 | 2010-04-21 | Medical College of Georgia Research Institute, Inc | Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance |
| US7763251B2 (en) | 2002-04-12 | 2010-07-27 | Medical College Of Georgia Research Institute, Inc. | Kits to assess the risk of tumor progression |
| DE10229872A1 (de) * | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
| US20040253606A1 (en) | 2002-11-26 | 2004-12-16 | Protein Design Labs, Inc. | Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators |
| AU2003302820A1 (en) | 2002-12-05 | 2004-06-30 | Diadexus, Inc. | Compositions, splice variants and methods relating to breast specific genes and proteins |
| EP1569690B1 (en) | 2002-12-13 | 2011-07-27 | Mitra Medical Technology AB | Antilymphoma targeting agents with effector and affinity functions linked by a trifunctional reagent |
| DE10261223A1 (de) | 2002-12-20 | 2004-07-08 | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH | Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen |
| EP1613308A4 (en) | 2003-03-27 | 2008-02-20 | Lankenau Inst Medical Res | CANCER TREATMENT METHODS |
| US7598287B2 (en) | 2003-04-01 | 2009-10-06 | Medical College Of Georgia Research Institute, Inc. | Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities |
| US20050186289A1 (en) | 2003-04-01 | 2005-08-25 | Medical College Of Georgia Research Institute, Inc. | Regulation of T cell-mediated immunity by D isomers of inhibitors of indoleamine-2,3-dioxygenase |
| WO2005017163A2 (en) | 2003-08-15 | 2005-02-24 | Imperial College Innovations Limited | Phenotypic knockout of cell-surface proteins |
| WO2005036127A2 (en) | 2003-10-02 | 2005-04-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for identifying target cell cytolytic lymphocytes in a sample |
| EP1773846A4 (en) * | 2004-07-13 | 2008-10-08 | Univ British Columbia | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE (IDO) |
| US20060110371A1 (en) | 2004-11-23 | 2006-05-25 | Institut Pasteur | Control of indoleamine 2,3 deoxygenase expression and activity |
| ES2523172T3 (es) | 2005-02-04 | 2014-11-21 | Survac Aps | Vacuna de péptido de survivina |
| SG10201809390QA (en) | 2005-05-10 | 2018-11-29 | Incyte Holdings Corp | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
| US7468186B2 (en) | 2005-07-22 | 2008-12-23 | City Of Hope | Polyomavirus cellular epitopes and uses therefor |
| GB0519303D0 (en) | 2005-09-21 | 2005-11-02 | Oxford Biomedica Ltd | Chemo-immunotherapy method |
| CA2953782C (en) * | 2005-09-23 | 2023-09-12 | Centro Superior De Investigaciones Cientificas | Cell populations having immunoregulatory activity, method for isolation and uses |
| WO2007095050A2 (en) | 2006-02-09 | 2007-08-23 | Incyte Corporation | N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase |
| WO2007115068A2 (en) | 2006-03-30 | 2007-10-11 | Indiana University Research And Technology Corporation | Genetic variants in the indoleamine 2,3-dioxygenase gene |
| EP2023715B1 (en) * | 2006-05-18 | 2014-01-08 | Lankenau Institute for Medical Research | Indoleamine-2, 3-dioxygenase-2 |
| WO2008085828A2 (en) * | 2007-01-03 | 2008-07-17 | The Johns Hopkins University | Peptide modulators of angiogenesis and use thereof |
| JP2011520783A (ja) | 2008-04-17 | 2011-07-21 | エルレフ ホスピタル | インドールアミン２，３−ジオキシゲナーゼに基づく免疫療法 |
-
2009
- 2009-04-17 JP JP2011504314A patent/JP2011520783A/ja active Pending
- 2009-04-17 LT LTEP17194619.7T patent/LT3320912T/lt unknown
- 2009-04-17 CN CN200980122844.0A patent/CN102088994B/zh active Active
- 2009-04-17 ES ES17194619T patent/ES2870596T3/es active Active
- 2009-04-17 PL PL09753556T patent/PL2280721T3/pl unknown
- 2009-04-17 AU AU2009253539A patent/AU2009253539B2/en active Active
- 2009-04-17 LT LTEP09753556.1T patent/LT2280721T/lt unknown
- 2009-04-17 HU HUE17194619A patent/HUE055338T2/hu unknown
- 2009-04-17 SI SI200932129T patent/SI3320912T1/sl unknown
- 2009-04-17 PT PT97535561T patent/PT2280721T/pt unknown
- 2009-04-17 EP EP21157371.2A patent/EP3915570A1/en active Pending
- 2009-04-17 DK DK17194619.7T patent/DK3320912T3/da active
- 2009-04-17 CA CA2721150A patent/CA2721150C/en active Active
- 2009-04-17 NO NO09753556A patent/NO2280721T3/no unknown
- 2009-04-17 HU HUE09753556A patent/HUE037973T2/hu unknown
- 2009-04-17 PL PL17194619T patent/PL3320912T3/pl unknown
- 2009-04-17 US US12/988,124 patent/US9433666B2/en active Active
- 2009-04-17 DK DK09753556.1T patent/DK2280721T3/da active
- 2009-04-17 PT PT171946197T patent/PT3320912T/pt unknown
- 2009-04-17 EP EP09753556.1A patent/EP2280721B1/en active Active
- 2009-04-17 SI SI200931791T patent/SI2280721T1/en unknown
- 2009-04-17 WO PCT/DK2009/000095 patent/WO2009143843A1/en active Application Filing
- 2009-04-17 EP EP17194619.7A patent/EP3320912B1/en active Active
- 2009-04-17 NZ NZ588757A patent/NZ588757A/en unknown
- 2009-04-17 ES ES09753556.1T patent/ES2657963T3/es active Active
- 2009-04-17 CN CN201410247727.XA patent/CN104056261B/zh active Active
-
2010
- 2010-10-17 IL IL208781A patent/IL208781A/en active IP Right Grant
- 2010-11-10 ZA ZA2010/08056A patent/ZA201008056B/en unknown
-
2015
- 2015-03-17 JP JP2015052888A patent/JP6016966B2/ja active Active
-
2016
- 2016-08-08 US US15/231,075 patent/US10258678B2/en active Active
-
2018
- 2018-02-12 CY CY20181100171T patent/CY1120352T1/el unknown
- 2018-02-15 HR HRP20180282TT patent/HRP20180282T1/hr unknown
-
2019
- 2019-01-29 US US16/261,114 patent/US11324813B2/en active Active
-
2021
- 2021-05-13 HR HRP20210766TT patent/HRP20210766T1/hr unknown
- 2021-06-28 CY CY20211100572T patent/CY1124279T1/el unknown
-
2022
- 2022-03-17 US US17/697,732 patent/US20220202922A1/en not_active Abandoned
- 2022-04-15 US US17/721,577 patent/US11648302B2/en active Active
-
2023
- 2023-04-10 US US18/298,263 patent/US20230233657A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201008056B (en) | Indoleamine 2,3-dioxygenase based immunotherapy | |
| HRP20180662T1 (hr) | 1,2,5-oksadiazoli kao inhibitori indolamin 2,3-dioksigenaze | |
| ZA201205788B (en) | 1,2,4-triazine-4-amine derivatives | |
| SI2384326T1 (sl) | Pirolo(2,3-d)pirimidinske spojine | |
| EP2361902A4 (en) | 4,6-DIAMINONICOTINSÄUREAMIDVERBINDUNG | |
| EP2376105A4 (en) | NKG2D-FC FOR IMMUNOTHERAPY | |
| EP2377874A4 (en) | Antioxidant | |
| EP2351732A4 (en) | NEW RAMALINE CONNECTION AND ITS USE | |
| ZA201008657B (en) | 4,5-dihydro-oxazol-2-yl derivatives | |
| MY165626A (en) | 1,2,4,-triazolone derivative | |
| PL2234635T3 (pl) | Immunoterapia oparta na białkach rhoc | |
| SI2266990T1 (sl) | Spojina 3-fenilpirazolo(5,1-b)tiazola | |
| EP2377875A4 (en) | ANTIOXIDANTS | |
| HK1162032A1 (en) | 1,1,1-trifluoro-2-hydroxypropyl compounds 111--2- | |
| HK1161684A1 (en) | 5,6-dihydro-1h-pyridin-2-one compounds 56- -1h--2- | |
| GB2461167B (en) | Novel amidoxime derivatives |